Brendan Frett

University of Arkansas System

H指数:24

被引数:1,413

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Discovery of quinazoline-based dual RET/Aurora B inhibitors for non-small cell lung cancer

基于喹唑啉的RET/Aurora B双重抑制剂在非小细胞肺癌中的发现

Bioorganic Chemistry

IF4.7

2026-08-010

PRE

Discovery of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRK/PTK6 inhibitors

新型1H-吡唑并[3,4-d]嘧啶衍生物作为BRK/PTK6抑制剂的发现

European Journal of Medicinal Chemistry

IF5.9

2025-09-110

PRE

Epigenetic dysregulation and therapeutic targeting of RET receptor tyrosine kinase in high-risk KMT2A-rearranged acute myeloid leukaemia

表观遗传失调及RET受体酪氨酸激酶在KMT2A重排高风险急性髓系白血病中的治疗靶向

BRITISH JOURNAL OF HAEMATOLOGY

IF3.8

2025-09-010

PRE

Transforming Growth Factor-β Receptor 1 and Mitogen-Activated Protein 4 Kinase 4 Dual Inhibitor, TK-850, Reduces Renal Fibrosis in Unilateral Ureteral Obstructed Mice

转化生长因子-β受体1和促分裂原活化蛋白4激酶4双抑制剂，TK-850，减轻单侧输尿管梗阻小鼠的肾纤维化

pharmacology and experimental therapeutics

IF0

2025-06-250

PRE

An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)

关于重排于转染（RET）激酶抑制剂的更新专利综述（2022年至今）

Expert Opinion on Therapeutic Patents

IF4.6

2025-06-170

PRE

Discovery of the DNA-PKcs inhibitor DA-143 which exhibits enhanced solubility relative to NU7441

SCIENTIFIC REPORTS

IF3.9

2024-08-280

OAAI

Discovery of 9 H-pyrimido[4,5- b ]indole derivatives as dual RET/ TRKA inhibitors

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2024-05-010

PRE

Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules

RSC MEDICINAL CHEMISTRY

IF3.6

2024-01-017

PRE

Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-10-109

An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present)

转染期间重排 (RET) 激酶抑制剂的最新专利综述 (2016至今)

EXPERT OPINION ON THERAPEUTIC PATENTS

IF4.6

2022-10-182

PRE

Targeting TGF-beta: triumphs and challenges

以tgf-beta为目标: 胜利与挑战

FUTURE MEDICINAL CHEMISTRY

IF3.4

2022-02-132

PRE

Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-01-279

FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms

RSC MEDICINAL CHEMISTRY

IF3.6

2022-01-0117

Discovery of 4-aminoquinolines as highly selective TGFbR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2021-12-013

PREAI

Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2021-12-0115

OAAI

Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors

新型非激酶tgf β 途径抑制剂酞嗪的发现和生物学评价

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2021-11-012

OAAI

Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-08-1719

OAAI

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases

SCIENTIFIC REPORTS

IF3.9

2021-08-098

OAAI

Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2021-04-0123

OAAI

Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach

CHEMMEDCHEM

IF3.4

2021-03-083

Brendan Frett

个人简介

教育背景

工作经历

荣誉奖项

研究方向